GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Liabilities-to-Assets

Gilead Sciences (BUE:GILD) Liabilities-to-Assets : 0.69 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Gilead Sciences's Total Liabilities for the quarter that ended in Mar. 2024 was ARS32,720,173 Mil. Gilead Sciences's Total Assets for the quarter that ended in Mar. 2024 was ARS47,426,011 Mil. Therefore, Gilead Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.69.


Gilead Sciences Liabilities-to-Assets Historical Data

The historical data trend for Gilead Sciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Liabilities-to-Assets Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.73 0.69 0.66 0.63

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.66 0.64 0.63 0.69

Competitive Comparison of Gilead Sciences's Liabilities-to-Assets

For the Drug Manufacturers - General subindustry, Gilead Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Liabilities-to-Assets falls into.



Gilead Sciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Gilead Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=14214736.013/22427125.02
=0.63

Gilead Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=32720173.056/47426010.806
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (BUE:GILD) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Gilead Sciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BUE:GILD) Headlines

From GuruFocus

Q4 2022 Gilead Sciences Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Gilead Sciences Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Gilead Sciences Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Gilead Sciences Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Gilead Sciences Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Gilead Sciences Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024